An interventional study of Digital-Supported Informed Consent Pathway and Standard Physician-Led Informed Consent in Informed Consent, Patient Education and Patient Comprehension, sponsored by Unity Health Toronto. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.
Sponsored by Unity Health Toronto · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Patient Satisfaction with a site in Canada — 6 open to participants now, 9 under way, none of them phase 3. Patient Satisfaction · Canada.
Among the 49 studies in Patient Satisfaction with a site in Canada, this one is the 15th largest by planned enrollment of the 43 interventional ones that give a count, is one of 4 that started in 2026, is one of 41 with no phase, and was the 49th registered.
882 studies on the registry are indexed under Patient Satisfaction; 205 are open to participants now.
Browse Patient Satisfaction studies →6 of the 49 studies in Patient Satisfaction with a site in Canada are open now. Recruiting first, the newest first:
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+ · Women only
University Health Network, Toronto · Sites in Canada
Ages 18+
University of British Columbia · Sites in Canada
Ages 18+
St. Justine's Hospital · Sites in Canada
Ages 18+ · Women only
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 102 Patient Satisfaction studies recruiting now, 63 (62%) set no upper age limit and 31 (30%) stop at 75 or younger; 14 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 96 across 627 interventional studies indexed under Patient Satisfaction.
Median enrollment 101 across the 43 interventional studies, 150 across the 6 observational. Of the 34 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 49 have an industry lead sponsor. The 10 most frequent:
Unity Health Toronto is the lead sponsor of 447 studies on the registry; 81 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Unity Health Toronto has 2 studies filed under Patient Satisfaction — fewer than ten, so there is no comparison to draw.
4 of the studies in Patient Satisfaction with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07187427St. Justine's HospitalIncidence of Pruritus Using Intrathecal Fentanyl Versus Epidural Fentanyl to Initiate Labour Analgesia. | 2026-12 |
| NCT07686133University Health Network, TorontoDigital Education in Colorectal Cancer Patients | 2027-01 |
| NCT06459271University Health Network, TorontoFeasibility of CALM in Patients With Ovarian Cancer | 2027-02 |
| NCT02117856University of British ColumbiaComplete Lower Dentures on 1 or 2 Implants | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 49 studies in Patient Satisfaction with a site in Canada, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate whether a digital-supported informed consent process improves patient understanding before advanced therapeutic endoscopy procedures.
Patients undergoing advanced therapeutic endoscopy are often asked to make decisions about procedures that may be complex and involve important risks, benefits, and alternatives. Standard informed consent is usually provided through discussion with the treating physician. However, this process can vary between clinicians and may be affected by time pressures in busy endoscopy units.
In this study, eligible adult patients scheduled for elective advanced therapeutic endoscopy will be randomly assigned to one of two consent pathways. One group will receive standard physician-led informed consent. The other group will receive a digital-supported consent pathway that includes a standardized procedure-specific educational video, an offline artificial intelligence-based question-answering tool, and final confirmation with the treating physician before the procedure.
The digital tool is designed to provide plain-language information about the procedure, including why it is being done, expected benefits, common and serious risks, alternatives, what to expect before and after the procedure, and the patient's right to ask questions or decline the procedure. The AI question-answering tool will use only investigator-approved educational content and will not provide individualized medical advice. Questions requiring patient-specific medical judgment will be directed back to the treating clinical team.
The main outcome of the study is patient comprehension of the consent information, measured after the assigned consent process and before the procedure. The study will also evaluate patient anxiety, satisfaction, confidence in decision-making, usability of the consent process, workflow outcomes, and consent-related safety or ethical concerns.
This is a pragmatic multicenter randomized controlled trial evaluating digital-supported informed consent compared with standard physician-led informed consent for adults undergoing elective advanced therapeutic endoscopy.
The study will be conducted in three sequential phases. In the first phase, the digital consent tool will be developed through an iterative co-design process involving the study team, a specialist engineer, and at least one patient partner. The tool will include a standardized procedure-specific educational video and an offline artificial intelligence-based question-answering interface. The AI component will be developed using only investigator-approved educational materials, standardized consent language, and curated frequently asked questions. It will not browse the internet, retrieve external information in real time, or provide individualized medical advice.
In the second phase, a pilot study will assess feasibility, usability, acceptability, and operational performance of the digital consent pathway. The pilot will assess whether participants can access and complete the video and AI interface, whether the digital tool functions as intended, whether the survey-based outcome assessment workflow is practical, and whether refinements are needed before the full randomized trial. The pilot phase is not intended to provide definitive comparative effectiveness results.
In the third phase, the finalized intervention will be evaluated in a multicenter, parallel-group randomized controlled trial. Eligible participants will be randomized in a 1:1 ratio to either standard physician-led informed consent or the digital-supported consent pathway. Randomization will be centralized and concealed using a secure web-based system, with stratification by site and potentially by major procedure category.
Participants assigned to the standard consent arm will receive the usual physician-led informed consent process according to local clinical practice. Participants assigned to the digital-supported arm will receive access to a procedure-specific digital consent package, ideally before the procedure. The digital package will include a standardized educational video explaining the nature of the procedure, the reason it is being performed, expected benefits, major and common risks, reasonable alternatives, what to expect before and after the procedure, and the right to ask questions or decline the procedure. After viewing the video, participants may ask questions through a secure offline AI-based interface. The tool will provide plain-language responses grounded only in pre-approved study materials and will redirect individualized or high-risk questions to the treating clinical team.
In both study arms, final procedural consent remains the responsibility of the treating physician. In the digital-supported arm, the physician will conduct a final confirmation discussion before the procedure to review unresolved questions, address individualized risks, benefits, and alternatives, confirm patient understanding, and complete standard institutional consent documentation.
The primary outcome is patient comprehension of informed consent information, assessed immediately after completion of the assigned consent pathway and before the procedure. The comprehension assessment will address key domains of informed consent, including the nature of the procedure, indication, risks, benefits, alternatives, right to ask questions or refuse, and basic expectations before and after the procedure.
Secondary outcomes include pre-procedural anxiety, satisfaction with the consent process, decisional confidence or self-efficacy, perceived usability and acceptability, perceived opportunity to ask questions, preference for future consent format, physician time spent on consent, staff time where measurable, consent-related delays, same-day cancellation or deferral due to unresolved consent concerns, and need for additional pre-procedural contact related to consent. Digital process outcomes will include video completion rate, AI tool utilization rate, number and categories of patient questions, frequency of questions escalated to clinician review, and completion of the intervention before arrival. Safety and ethical quality outcomes will include withdrawal of procedural consent after the assigned intervention, patient-reported misunderstanding, complaints related to the consent process, protocol deviations involving consent, and any adverse event judged related to misunderstanding of instructions or procedural expectations.
The study is designed to minimize collection of identifiable information. Study outcomes will be collected primarily through secure survey links, and the research dataset will not include direct identifiers such as names, dates of birth, medical record numbers, addresses, email addresses, telephone numbers, or IP addresses. Any retained AI interaction data will be anonymized and will not be linked to participant identifiers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to this arm will receive a digital-supported informed consent pathway before elective advanced therapeutic endoscopy. The pathway includes a standardized procedure-specific educational video, an offline AI-based question-answering tool using investigator-approved content, and final physician confirmation before the procedure. The treating physician remains responsible for individualized risk discussion and final procedural consent.
Behavioral: Digital-Supported Informed Consent Pathway
Participants assigned to this arm will receive the usual physician-led informed consent process before elective advanced therapeutic endoscopy according to local clinical practice. The treating physician will review the procedure, risks, benefits, alternatives, and patient questions, and will complete standard institutional procedural consent documentation.
Behavioral: Standard Physician-Led Informed Consent
The digital-supported informed consent pathway consists of a standardized procedure-specific educational video, an offline AI-based question-answering interface, and final physician confirmation. The video explains the nature of the procedure, indication, expected benefits, major and common risks, alternatives, what to expect before and after the procedure, and the patient's right to ask questions or decline. The AI tool provides plain-language responses based only on investigator-approved educational materials and redirects individualized or high-risk questions to the treating clinical team.
Also known as: Digital consent pathway, Video and AI-supported consent
The standard physician-led informed consent process consists of usual pre-procedure counseling by the treating physician according to local clinical practice. The physician discusses the procedure, indication, expected benefits, risks, alternatives, and patient questions, and completes standard institutional procedural consent documentation before the advanced therapeutic endoscopy procedure.
Also known as: Usual consent, Standard consent process
Patient Comprehension of Informed Consent Information
Patient comprehension will be assessed using a structured procedure-specific comprehension instrument after the assigned consent pathway. The instrument will assess understanding of the nature of the procedure, purpose or indication, risks, benefits, alternatives, right to ask questions or refuse, and expectations before and after the procedure.
Time frame: Immediately after the assigned consent pathway and before sedation/procedure
Pre-Procedural Anxiety
Participant-reported anxiety after completion of the assigned consent pathway, assessed using a study questionnaire or validated anxiety measure, as finalized in the study assessment plan.
Time frame: Immediately after the assigned consent pathway and before sedation/procedure
Satisfaction With Consent Process
Participant-reported satisfaction with the assigned consent process, including perceived clarity and helpfulness of the information provided.
Time frame: Immediately after the assigned consent pathway and before sedation/procedure
Decisional Confidence or Self-Efficacy
Participant-reported confidence in the decision to proceed with the procedure and perceived ability to make an informed decision after the consent process.
Time frame: Immediately after the assigned consent pathway and before sedation/procedure
Usability and Acceptability of Consent Process
Participant-reported usability and acceptability of the assigned consent process. For participants in the digital-supported arm, this will include perceived usability and acceptability of the video and AI-based question-answering tool.
Time frame: Immediately after the assigned consent pathway and before sedation/procedure
Perceived Opportunity to Ask Questions
Participant-reported perception of whether they had adequate opportunity to ask questions and have concerns addressed during the consent process.
Time frame: Immediately after the assigned consent pathway and before sedation/procedure
Preference for Future Consent Format
Participant preference for future consent format, including whether they would prefer standard physician-led consent, digital-supported consent, or a combined approach in future procedures.
Time frame: Immediately after the assigned consent pathway and before sedation/procedure
Physician Time Spent on Consent
Total physician time spent on the consent process, measured where feasible using workflow tracking or routine operational data.
Time frame: From start to completion of the consent process on the procedure day
Consent-Related Staff Time
Total staff time related to the consent process, where measurable using workflow tracking or routine operational data.
Time frame: From start to completion of the consent process on the procedure day
Consent-Related Delay
Delay attributable to the consent process, measured where feasible using routine operational or workflow data.
Time frame: Procedure day, before procedure start
Same-Day Cancellation or Deferral Due to Consent Concerns
Proportion of participants whose procedure is canceled or deferred on the same day because of unresolved consent-related concerns.
Time frame: Procedure day
Additional Pre-Procedural Contact Related to Consent
Need for additional pre-procedural contact with the clinical or research team related to consent questions or concerns.
Time frame: From enrollment to procedure start
Video Completion Rate
Proportion of participants assigned to the digital-supported arm who complete the standardized procedure-specific educational video.
Time frame: Before procedure start
AI Tool Utilization Rate
Proportion of participants assigned to the digital-supported arm who use the offline AI-based question-answering tool.
Time frame: Before procedure start
Number and Categories of Patient Questions Asked
Number and categories of questions submitted by participants through the digital question-answering interface.
Time frame: Before procedure start
Frequency of Questions Escalated to Clinician Review
Number and proportion of participant questions that are flagged as individualized, complex, high-risk, or requiring clinician review.
Time frame: Before procedure start
Digital Intervention Completion Before Arrival
Proportion of participants assigned to the digital-supported arm who complete the digital consent pathway before arrival for the procedure.
Time frame: Before arrival for procedure
Withdrawal of Procedural Consent After Assigned Intervention
Proportion of participants who withdraw procedural consent after completing the assigned consent pathway.
Time frame: After assigned consent pathway through procedure start
Questionnaire Assessing Patient Understanding
Participant-reported misunderstanding related to the consent information, procedure instructions, or procedural expectations identified after the procedure.
Time frame: immediately after the intervention
Complaints Related to Consent Process
Number of participant complaints related to the consent process.
Time frame: immediately after the intervention
Protocol Deviations Involving Consent
Number of protocol deviations related to delivery or documentation of the study consent or procedural consent process.
Time frame: From enrollment through study follow-up
Adverse Events Related to Misunderstanding of Instructions or Procedural Expectations
Any adverse event judged to be related to misunderstanding of procedural instructions or expectations following the assigned consent pathway.
Time frame: immediately after the intervention
Retention of Key Knowledge
Participant retention of key consent-related knowledge at short follow-up after the procedure.
Time frame: immediately after the intervention
Subgroup Differences in Comprehension and Consent Outcomes
Exploratory subgroup analyses by age, education, prior endoscopy experience, digital literacy, procedure type, and site.
Time frame: immediately after the intervention
Comparative Performance Across Study Settings
Exploratory comparison of intervention performance across North American and European participating sites.
Time frame: immediately after the intervention
Plan to share: No — Individual participant data will not be shared because the study is designed to collect anonymous, non-identifiable survey-based data without direct participant identifiers or a participant linking log. The protocol does not include a formal plan for external sharing of participant-level data. Aggregate study results may be reported in publications and presentations.
Start is estimated for Sep 2026; primary completion for Dec 2027, 15 months later.
Of 368 non-industry interventional studies with no phase under Patient Satisfaction, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 15 months is above that.
Counting every sponsor, half of 370 studies reached it within 12 months; a quarter within 6 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.